



WELCURE DRUGS & PHARMACEUTICALS LTD.

Regd. Off. : B-9 & 10, Laxmi Towers, L.S.C., Block C, Saraswati Vihar, Delhi -110034.
CIN No. L24232DL1996PLC227773

Date: 16th July, 2022

BSE Limited

Phiroze Jeejeebhoy Towers
Dalal Street, Mumbai-400001

Scrip Code: 524661--Welcure Drugs & Pharmaceuticals Ltd.

Sub: Un-audited Financial Results for the Quarter ended 30.06.2022

Ref: Outcome of Board of Directors Meeting- 16th July, 2022

Respected Sir,

Pursuant to the provisions of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company in its meeting held today Saturday, 16th July, 2022 at 11:30 am and concluded at 12:35 pm am, *inter-alia*, approved the Un-Audited Financial Results of the Company for the Quarter ended 30th June, 2022.

We enclose copies of the following:

1. Un-audited Financial Results for the Quarter ended 30th June, 2022; and
2. Limited Review Report of Un-Audited Financial Results for the said period.

We request you to take the same on record.

Thanking you

Yours faithfully

For Welcure Drugs & Pharmaceuticals Limited


(Mitashi Bisaria)

Director & Company Secretary
DIN: 08660802

Encl.: a/a



V.P. Gupta & Co.

Chartered Accountants

LIMITED REVIEW REPORT
(For the Quarter ended on June 30, 2022)

To
The Board of Directors,
Welcure Drugs & Pharmaceuticals Limited

1. We have reviewed the accompanying Statement of Un-audited Financial Results of Welcure Drugs & Pharmaceuticals Limited ("the Company") for the Quarter ended June 30, 2022 ("the Statement") attached herewith, being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015 (the 'Regulations') as amended, read with SEBI Circular No. CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").
2. This Statement which is the responsibility of the Company's Management and approved by the Board of Directors on 16th July, 2022, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind-AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India. Our responsibility is to issue a report on the statement based on our review.
3. We conducted our review of the statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information performed by the Independent Auditors of the Entity", issued by the Institute of Chartered Accountants of India. This Standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.



288, Ghalib Apartments, Parwana Road, Pitampura, Delhi 110034, India

Ph. :- 91-11-27020321, 9313675636 Email:- tax@vpguptaandco.com



V.P. Gupta & Co.

Chartered Accountants

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the aforesaid Indian Accounting Standards prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India, that has not disclosed the information required to be disclosed in terms of the Regulation, read with the Circular, including the manner in which it is to be disclosed, or that it contains any material misstatements.

Place: Delhi
Date: 16.07.2022

For V.P. Gupta & Co.
Chartered Accountants
FRN: 000699N



M No.: 080557
UDIN: 22080557AMZQAK9301

288, Ghalib Apartments, Parwana Road, Pitampura, Delhi 110034, India

Ph. :- 91-11-27020321, 9313675636 Email:- tax@vpguptaandco.com

WELCURE DRUGS AND PHARMACEUTICALS LTD

Regd. Office: B-9& 10, Laxmi Towers LSC, C-Block, Saraswati Vihar, Delhi-110034

CIN: L24232DL1996PLC227773

Email Id: investor.welcure@gmail.com

Statement of Un-audited Financial Results for the Quarter ended 30th June, 2022

Sr. No.	Particulars	(Figures in Lakhs)			
		Quarter Ended			Year ended
		30-Jun-22 Un-Audited	31-Mar-22 Audited	30-Jun-21 Un-Audited	31-Mar-22 Audited
I	Income				
	a) Revenue from operations	-	-	-	-
	b) Other Operating Income	-	8.25	2.25	10.50
	Total Income from operations (net)	-	8.25	2.25	10.50
II	Other Income	-	-	-	-
III	Total Income (I+II)	-	8.25	2.25	10.50
IV	Expenses				
	(a) Cost of raw materials consumed	-	-	-	-
	(b) Purchases of stock-in-trade	-	-	-	-
	(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	-	-	-	-
	(d) Employee benefits expenses	0.36	0.36	0.21	1.29
	(e) Finance Cost	-	-	-	-
	(f) Depreciation and amortisation expense	-	-	-	-
	(g) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	5.29	1.19	4.44	6.85
	Total Expenses	5.65	1.55	4.65	8.14
V	Profit/ (Loss) Before Exceptional and Extraordinary Items and Tax (III-IV)	(5.65)	6.70	(2.40)	2.36
VI	Exceptional Items	-	-	-	-
VII	Profit/ (Loss) before extraordinary items and Tax (V-VI)	(5.65)	6.70	(2.40)	2.36
VIII	Extraordinary items	-	-	-	-
IX	Profit before tax (VII- VIII)	(5.65)	6.70	(2.40)	2.36
X	Tax Expenses				
	Current Tax	-	-	-	-
	Deferred Tax	-	-	-	-
XI	Profit (Loss) for the period from continuing operations (IX-X)	(5.65)	6.70	(2.40)	2.36
XII	Net Profit/ (Loss) from discontinuing operation (before Tax)	-	-	-	-
XIII	Tax Expense of discontinuing operations	-	-	-	-
XIV	Net Profit/ (Loss) from discontinuing operation after Tax (XII-XIII)	-	-	-	-
XV	Net Profit/ (Loss) for the Period (XI+XIV)	(5.65)	6.70	(2.40)	2.36
XVI	Share of profit / (loss) of associates	-	-	-	-
XVII	Share of profit / (loss) of Minority	-	-	-	-
XVIII	Net Profit/ (Loss) after taxes, minority interest and share of profit/(loss) of associates	(5.65)	6.70	(2.40)	2.36
XIX	Other Comprehensive Income	-	-	-	-
XX	Total Comprehensive Income for the period (XVIII+XIX)	(5.65)	6.70	(2.40)	2.36
XXI	Paid-up share capital (Face value of Rs.10/- per share)	1,211.86	1,211.86	1,211.86	1,211.86
XXII	Reserves excluding Revaluation Reserves as per balance sheet of previous accounting year	-	-	-	(1,202.56)
XXIII	Earning Per Share (of Rs. 10/- each) (not annualised) A) Basic B) Diluted	(0.00) 0.06	0.06	(0.02) 0.02	0.02

Notes:

- The Financial Results of the Company has been prepared in accordance with the Indian Accounting Standard (Ind AS) prescribed under Section 133 of Companies Act, 2013 read with relevant rules issued thereunder.
- The Statement of Unaudited Financial results for the Quarter ended June 30, 2022 have been reviewed by the audit committee and approved by the Board of Directors at their respective meeting held on 15th July, 2022. There are no qualifications in the report issued by the auditors.
- There were no Investor Complaints pending during the quarter ended June 30, 2022
- As the Company is mainly operating in one reportable business segment, hence the disclosure requirements of Indian Accounting Standard (Ind AS-108) "Operating Segment" is not applicable.
- The Previous Quarter ended figures have been re-grouped/ re-arranged, wherever necessary.
- There is no need to provide any reconciliation as required by the circular dated July 05, 2016, since there is no change in the figures due to transit from the previous Indian GAAP to Ind-AS.

For Welcure Drugs & Pharmaceuticals Limited

Place: Delhi
Date: 16.07.2022

Sudhir Chandra
Managing Director
DIN: 00323545

